BRIUMVI
NDC product · U.S. Food and Drug Administration (openFDA) · United States
-
Product NDC
73150-150 -
Package NDC
73150-150-06 -
Application number
BLA761238 -
SPL ID
4b34fc66-ea84-161b-e063-6294a90ac575 -
SPL set ID
3a77cd8c-811b-407c-9140-d0c5c26435c2 -
UNII
U59UGK3IPC -
RxCUI
2626353 -
RxCUI
2626359
What the source publishes
- Labeler
- TG Therapeutics, Inc.
- Active ingredients
- ublituximab
- Form
- INJECTION, SOLUTION, CONCENTRATE
- Routes
- INTRAVENOUS
- Administrative status
- present-in-source-snapshot
- Marketing status
- BLA
- Product type
- HUMAN PRESCRIPTION DRUG
- Prescription
- Prescription or restricted
Names this record is found by
Complete source data
{
"name": "BRIUMVI",
"splId": "4b34fc66-ea84-161b-e063-6294a90ac575",
"labels": [
{
"setId": "3a77cd8c-811b-407c-9140-d0c5c26435c2",
"labelUrl": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3a77cd8c-811b-407c-9140-d0c5c26435c2",
"labelPdfUrl": "https://dailymed.nlm.nih.gov/dailymed/downloadpdffile.cfm?setId=3a77cd8c-811b-407c-9140-d0c5c26435c2"
}
],
"routes": [
"INTRAVENOUS"
],
"labeler": "TG Therapeutics, Inc.",
"finished": true,
"packaging": [
{
"sample": false,
"description": "1 VIAL, SINGLE-DOSE in 1 CARTON (73150-150-06) / 6 mL in 1 VIAL, SINGLE-DOSE",
"package_ndc": "73150-150-06",
"identifierStatus": "well-formed",
"marketing_start_date": "20221228"
}
],
"productId": "73150-150_4b34fc66-ea84-161b-e063-6294a90ac575",
"useDomain": "unknown",
"dosageForm": "INJECTION, SOLUTION, CONCENTRATE",
"productNdc": "73150-150",
"deaSchedule": null,
"genericName": "ublituximab",
"productType": "HUMAN PRESCRIPTION DRUG",
"listingStatus": "present-in-source-snapshot",
"targetSpecies": [],
"approvalStatus": "not-established-by-ndc-listing",
"labelAssociation": "openFDA-harmonized-set-ids; not a product-level approval match",
"marketingEndDate": null,
"activeIngredients": [
{
"name": "UBLITUXIMAB",
"strength": "150 mg/6mL"
}
],
"applicationNumber": "BLA761238",
"marketingCategory": "BLA",
"stateRestrictions": {
"status": "not-collected",
"observations": []
},
"useDomainEvidence": {
"basis": "unreviewed",
"field": null,
"value": null,
"version": 1,
"sourceId": "us.fda.ndc"
},
"marketingStartDate": "20221228",
"targetSpeciesStatus": "not-reported",
"prescriptionCategory": "prescription-or-restricted",
"harmonizedIdentifiers": {
"nui": [
"N0000175078",
"N0000175657"
],
"upc": [
"0373150150063"
],
"unii": [
"U59UGK3IPC"
],
"rxcui": [
"2626353",
"2626359"
],
"spl_set_id": [
"3a77cd8c-811b-407c-9140-d0c5c26435c2"
],
"pharm_class_epc": [
"CD20-directed Cytolytic Antibody [EPC]"
],
"pharm_class_moa": [
"CD20-directed Antibody Interactions [MoA]"
],
"manufacturer_name": [
"TG Therapeutics, Inc."
],
"is_original_packager": [
true
]
},
"listingExpirationDate": "20271231"
}
Read this record from your own software
The same record, with every field and its provenance, is one request away. An API key is free and works immediately.
curl -G "https://api.medifontis.com/v1/drugs/record" \
-H "Authorization: Bearer $MEDIFONTIS_API_KEY" \
--data-urlencode "country=us" \
--data-urlencode "sourceId=us.fda.ndc" \
--data-urlencode "id=us:fda:ndc:73150-150_4b34fc66-ea84-161b-e063-6294a90ac575"